TTrialPathMatch Me to Trials
← Back to trials
RecruitingChronic MigraineChronic Migraine, Headache

Efficacy of Nerve Block Versus Botox in Chronic Migraine Management

Eligible age

18–65 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical trial is to determine whether nerve block injections (specifically, supratrochlear and greater occipital nerve injections) are as effective as Botulinum toxin A (Botox) injections in treating chronic migraine in adults. The main questions it aims to answer are: * Do nerve block injections reduce the number of monthly migraine days compared to baseline? * Are there any differences in the frequency of migraine-related symptoms between the nerve block and Botox treatment groups? * Which treatment leads to higher patient satisfaction and improved quality of life? Participants in this study will: * Receive either nerve block injections or Botox injections every 12 weeks. * Visit the clinic once every month for follow-ups and assessments. * Maintain a headache diary to record the frequency and severity of their migraines and any adverse effects experienced. * Researchers will compare the outcomes of the two groups to determine if one treatment is superior in terms of efficacy and patient satisfaction.

Sponsor: Zagazig University

You may qualify if…

  • ✓ Adults aged 18 to 65 years.
  • ✓ Diagnosis of chronic migraine, defined as having headaches on 15 or more days per month for more than three months, with at least 8 of those days meeting criteria for migraine.
  • ✓ Ability to provide informed consent and comply with study requirements.
  • ✓ No changes in prophylactic migraine medications in the last 3 months.

You may not qualify if…

  • ✕ History of allergy or hypersensitivity to local anesthetics or Botulinum toxin.
  • ✕ Previous nerve block or Botox treatment within the last 6 months.
  • ✕ Significant comorbid psychiatric or neurological disorders that could interfere with study participation or evaluation.
  • ✕ Pregnancy or breastfeeding.
  • ✕ Contraindications to either treatment as per product labels.

Source: ClinicalTrials.gov · NCT06684249 · last updated 2024-11-12